Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Dan L. Eisenberg, Carol B Toris, Carl B. Camras

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

Original languageEnglish (US)
Pages (from-to)S105-S115
JournalSurvey of Ophthalmology
Volume47
Issue number4 SUPPL. 1
DOIs
StatePublished - Aug 2002

Fingerprint

latanoprost
Timolol
Glaucoma
Intraocular Pressure
Pharmaceutical Preparations
Eyelashes
Ocular Hypertension
Hyperemia
Bimatoprost
Travoprost
Growth

Keywords

  • Bimatoprost
  • Glaucoma
  • Intraocular pressure
  • Latanoprost
  • Ocular hypertension
  • Timolol
  • Travoprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bimatoprost and travoprost : A review of recent studies of two new glaucoma drugs. / Eisenberg, Dan L.; Toris, Carol B; Camras, Carl B.

In: Survey of Ophthalmology, Vol. 47, No. 4 SUPPL. 1, 08.2002, p. S105-S115.

Research output: Contribution to journalArticle

Eisenberg, Dan L. ; Toris, Carol B ; Camras, Carl B. / Bimatoprost and travoprost : A review of recent studies of two new glaucoma drugs. In: Survey of Ophthalmology. 2002 ; Vol. 47, No. 4 SUPPL. 1. pp. S105-S115.
@article{3912e1223dc94a2a91b47136aea73f04,
title = "Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs",
abstract = "Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.",
keywords = "Bimatoprost, Glaucoma, Intraocular pressure, Latanoprost, Ocular hypertension, Timolol, Travoprost",
author = "Eisenberg, {Dan L.} and Toris, {Carol B} and Camras, {Carl B.}",
year = "2002",
month = "8",
doi = "10.1016/S0039-6257(02)00327-2",
language = "English (US)",
volume = "47",
pages = "S105--S115",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Bimatoprost and travoprost

T2 - A review of recent studies of two new glaucoma drugs

AU - Eisenberg, Dan L.

AU - Toris, Carol B

AU - Camras, Carl B.

PY - 2002/8

Y1 - 2002/8

N2 - Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

AB - Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

KW - Bimatoprost

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost

KW - Ocular hypertension

KW - Timolol

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=0036668996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036668996&partnerID=8YFLogxK

U2 - 10.1016/S0039-6257(02)00327-2

DO - 10.1016/S0039-6257(02)00327-2

M3 - Article

C2 - 12204706

AN - SCOPUS:0036668996

VL - 47

SP - S105-S115

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 4 SUPPL. 1

ER -